Sovihep V Tablet
Prescription Required
Marketed By
zydus heptiza
Pack of
28 tablet
Salt Composition
Sofosbuvir 400mg + Velpatasvir 100mg
Storage
Keep in cold place
₹6500₹17500
62.86% Off
Inclusive of all taxes
1
Sovihep V Tablet
Delivering To: —
Overview
Sovihep V tablet is a combination of two antiviral drugs, Sofosbuvir and Velpatasvir. This medicine is used in the treatment of chronic Hepatitis C virus (HCV). Store this medicine at room temperature and keep it away from light and moisture. Chronic hepatitis C virus infection is the term used when the infection progresses into a stage that lasts for a long time. By stopping the hepatitis C virus from proliferating within your body, Sovihep V Tablet helps lower its number. This helps in infection control and speeds up your recovery. You must take this medication exactly as directed by your doctor, using the recommended dosage.
Indication
Hepatitis C
Uses
Chronic hepatitis C virus (HCV) infection
Side Effects
Sovihep V tablet may cause some serious and unwanted side effects that require immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.
Headache
Diarrhea
Nausea
Difficulty in breathing
Cough and chills
Loss of appetite
Muscle pain
Irregular heartbeat
Anemia
Dosage and Administration
Take this medicine as prescribed by your doctor. Do not skip or miss your dosing schedule. This medicine can be taken with or without food. In case of an overdose, the doctor will provide emergency medical treatment.
Mechanism of action
Sovihep V works by blocking different steps in the reproduction of viruses. Sofosbuvir with Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3, and 4 HCV infection with different regimens and durations depending on the HCV genotype. After the oral administration, the effect of this medicine can be observed in 2 to 4 hours.
Safety Advice
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Sovihep V tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Sovihep V tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
Missed Doses
It is advisable not to miss a dose of Sovihep V tablet. If you miss a scheduled dose of this medicine, contact your doctor immediately.
FAQs
Sovihep V tablet is a combination of two antiviral medicines, Sofosbuvir and Velpatasvir. It works by removing the virus from the blood over time.
It works by blocking different steps in the reproduction of viruses.
Some common side effects are nausea, fatigue, headache, anemia, rashes, muscle pain, insomnia, dizziness, blurred vision, etc.
It is not known whether it is safe or not. Please consult your doctor before consuming alcohol.
Store this medicine at room temperature. Keep it away from heat and light.
Trusted Medicines, Delivered Worldwide
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Reference
Feld, J. J., Jacobson, I. M.,Hézode, C., Asselah, T., Ruane, P., Gruener, N., Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610
Mangia, A., et al. (2020). Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5,552 patients from 12 cohorts. Liver International. Chandrashekhar, R., et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase III study with minimal monitoring in India. Hepatology International.
Uemura, Y., et al. (2021). Real‑world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Journal of Clinical and Experimental Hepatology. (Open access). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680481/
Lee, S., et al. (2022). Efficacy and safety of sofosbuvir/velpatasvir ± ribavirin in genotype 3 compensated cirrhosis: a meta-analysis. World Journal of Hepatology, 14(6), 1248–1259. https://doi.org/10.4254/wjh.v14.i6.1248
Takehara, T., Sakamoto, N., Nishiguchi, S., et al. (2019). Sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase III trial. Journal of Gastroenterology, 54(1), 87–95. https://doi.org/10.1007/s00535-018-1503-x
Related Products
MARKETER DETAILS
zydus heptiza
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.